Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (111-120 of 477) with videos related to

Pageof 48
Sort By:
Rheumatology (Oxford, England)|October 10, 2017
Assessment of skin involvement in systemic sclerosisGábor Kumánovics, Márta Péntek, Sangmee Bae, et al.
Clinical and Experimental Rheumatology|June 14, 2012
Clinical trial design in scleroderma: where are we and where do we go next?Lorinda Chung, Christopher P Denton, Oliver Distler, et al.
Rheumatology (Oxford, England)|February 11, 2010
Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trialPuja P Khanna, Daniel E Furst, Philip J Clements, et al.
The Journal of Rheumatology|December 7, 2005
A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritisDaniel E Furst, Roy Fleischmann, Elliott Kopp, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|June 1, 2012
Satisfaction and access to clinical care in a rheumatology clinic at a large urban medical centerHarsh Agrawal, M Cameron Hay, Elizabeth R Volkmann, et al.
Rheumatology (Oxford, England)|February 18, 2011
Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life studyTracy Frech, Ron D Hays, Paul Maranian, et al.
Arthritis and Rheumatism|April 12, 2011
Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitorsRobert A Terkeltaub, Daniel E Furst, Jennifer L Digiacinto, et al.
Seminars in Arthritis and Rheumatism|August 15, 2015
A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damageChristophe Meune, Dinesh Khanna, Jamil Aboulhosn, et al.
The Journal of Rheumatology|August 16, 2015
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 YearsRonald F van Vollenhoven, Roy M Fleischmann, Daniel E Furst, et al.
The Journal of Rheumatology|October 11, 2002
Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritisNihal H Fathi, Frank Mitros, John Hoffman, et al.
Pageof 48

Showing results (111-120 of 477) with videos related to

Sort By:
Pageof 48
Rheumatology (Oxford, England)|October 10, 2017
Assessment of skin involvement in systemic sclerosisGábor Kumánovics, Márta Péntek, Sangmee Bae, et al.
Clinical and Experimental Rheumatology|June 14, 2012
Clinical trial design in scleroderma: where are we and where do we go next?Lorinda Chung, Christopher P Denton, Oliver Distler, et al.
Rheumatology (Oxford, England)|February 11, 2010
Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trialPuja P Khanna, Daniel E Furst, Philip J Clements, et al.
The Journal of Rheumatology|December 7, 2005
A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritisDaniel E Furst, Roy Fleischmann, Elliott Kopp, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|June 1, 2012
Satisfaction and access to clinical care in a rheumatology clinic at a large urban medical centerHarsh Agrawal, M Cameron Hay, Elizabeth R Volkmann, et al.
Rheumatology (Oxford, England)|February 18, 2011
Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life studyTracy Frech, Ron D Hays, Paul Maranian, et al.
Arthritis and Rheumatism|April 12, 2011
Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitorsRobert A Terkeltaub, Daniel E Furst, Jennifer L Digiacinto, et al.
Seminars in Arthritis and Rheumatism|August 15, 2015
A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damageChristophe Meune, Dinesh Khanna, Jamil Aboulhosn, et al.
The Journal of Rheumatology|August 16, 2015
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 YearsRonald F van Vollenhoven, Roy M Fleischmann, Daniel E Furst, et al.
The Journal of Rheumatology|October 11, 2002
Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritisNihal H Fathi, Frank Mitros, John Hoffman, et al.
Pageof 48